The Sorin Bicarbon over 15 years clinical outcomes: multicentre experience in 1704 patients☆

Azarnoush, Kasra; Laborde, F; Riberolles, C. De

doi:10.1016/j.ejcts.2010.03.060

Cited by 19 publications

(20 citation statements)

References 23 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding long-term multicenter clinical results, Azarnoush and colleagues reported actuarial survival at 15 years of 61.4 % for AVR, 63.4 % for MVR, and 56.4 % for DVR [ 12 ]. They added that actuarial freedom from thromboembolism, anticoagulant-related hemorrhage, and endocarditis at 15 years was 88.8 %, 77.5 %, and 96.8 %, respectively, without any cases of structural failure of the prosthesis.…”

Section: Discussionmentioning

confidence: 99%

“…Long-term clinical experience with the St. Jude Medical and Carbomedics bileaflet mechanical valves for AVR and MVR have shown rates of thrombosis of between 0.73 % and 3.4 % per patient-year, and 10-year freedom from thrombosis of between 77 % and 94.2 % [ 12 – 21 ]. In addition, the rates of bleeding were between 0.52 % and 2.7 % per patient-year, and the 10-year freedom from bleeding ranged from 77 % to 96.4 %.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fifteen-year experience with the Bicarbon heart valve prosthesis in a single center

Misawa

Muraoka

Ohki

et al. 2015

J Cardiothorac Surg

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to evaluate retrospectively the clinical performance of the Bicarbon valve (Sorin Biomedica Cardio, Saluggia, Italy) implanted at our center in Japan.MethodsBetween January 1997 and December 2011, 415 patients in our institution were implanted with the Bicarbon valve. Nine of these recipients were excluded from the study because they had already undergone valve implantation and received a Bicarbon valve in a different position. The remaining patients were analyzed for evaluation of the postoperative clinical outcomes. Of the 406 patients (mean age 60.2 ± 11.7 years), 179 underwent aortic valve replacement (AVR), 149 mitral valve replacement (MVR), and 78 both aortic and mitral valve replacement (DVR).ResultsThere were 10 early deaths (2.5 %: 4 in the AVR group and 6 in the MVR group). Three hundred eighty-nine patients were followed up (95.8 % completeness of follow-up) with a mean follow-up of 6.6 ± 4.2 years overall (AVR 6.8 ± 4.2, MVR, 6.7 ± 4.4, and DVR 5.7 ± 3.4 years) and a cumulative follow-up of 2661 patient-years (1214, 1001, and 446 patient-years for AVR, MVR, and DVR, respectively). Ninety-nine patients died (3.7 % per patient-year: 22 valve-related and 77 valve-unrelated deaths). Survival at 10 years was 74.1 ± 4.0 % in the AVR group, 73.7 ± 4.2 % in the MVR group, and 61.0 ± 7.9 % in the DVR group. The linearized incidence of thromboembolic complications, bleeding complications, prosthetic valve endocarditis, paravalvular leaks, and sudden death in all patients was 0.5 %, 0.5 %, 0.2 %, 0.2 %, and 0.4 % per patient-year, respectively. The incidence of valve-related complications and reoperation was 1.6 % and 0.4 %, respectively. No other valve-related complications were observed.ConclusionsThe Bicarbon prosthetic heart valve has shown excellent clinical results and is associated with a low incidence of valve-related complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Fifteen-year experience with the Bicarbon heart valve prosthesis in a single center

Misawa

Muraoka

Ohki

et al. 2015

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…Схожие результаты за 10 лет наблю-дений получили K. Spiliopoulos и A. Haschemi [25]. Позд-нее K. Azarnoush и F. Laborde [28] продемонстрировали 15-летние наблюдения имплантации 1 900 клапанов Sorin Bicarbon в аортальную и митральную позиции и дока-зали низкие уровни летальности и клапанозависимых осложнений в очень отдаленном периоде, сопостави-мые с другими механическими клапанами (табл. 1 и 2).…”

Section: ретроспективные исследованияunclassified

Comparative studies of modern mechanical valve prosthesis (review)

Назаров¹,

Железнев²,

Богачев-Прокофьев³

et al. 2015

Patol krovoobrashch kardiokhir

View full text Add to dashboard Cite

More than 50 years have passed since the first successful heart valve replacement. Since then, many types of mechanical prostheses have been introduced. The prosthesis choice for the replacement of an affected valve is a major concern in valvular surgery. The introduction of a new heart valve prosthesis requires accurate data collection and data processing for a long follow-up period. In present article we sought to compare modern commercial available bileaflet foreign mechanical valve prosthesis for their long follow-up with Russian mechanical valve for aortic and mitral valve replacement.

show abstract

“…Therapy with 75–100 mg aspirin daily is also recommended. Some authors recommend an INR of 2.6–3.0 for aortic valve replacement patients and 3.0–3.5 for mitral valve replacement patients [ 9 , 10 ]. The Japanese guideline published in 2012, however, recommended a slightly lower INR between 2.0 and 3.0 [ 18 ].…”

Section: Thromboembolism and Bleeding Complicationsmentioning

confidence: 99%

“…The normal prosthetic valve function was restored after removing the suture material. Apparent hemolysis without a paravalvular leak has been rarely reported [ 9 , 56 , 57 ]. Borman et al [ 57 ] showed that simultaneous aortic and mitral valve replacement caused relatively increased hemolysis compared with single valve replacements, and indicated that all of six instances treated at their institution did not require reoperation.…”

Section: Nonstructural Dysfunctionmentioning

confidence: 99%

Valve-related complications after mechanical heart valve implantation

Misawa

2014

Surg Today

View full text Add to dashboard Cite

The number of heart valve surgeries is increasing, and 19,164 patients underwent heart valve surgery in Japan in 2011. The early mortality rate has remained stable for more than 10 years. Many patients now survive for many years, with a reported 10-year survival rate of at least 60 %. However, unfavorable complications can occur after valve surgery. Valve-related complications include thromboembolisms, bleeding complications and prosthetic valve endocarditis, followed by structural and nonstructural prosthetic valve dysfunctions. Our review of studies published after 2000 revealed that the rate of all valve-related complications was 0.7–3.5 % per patient-year. Thromboembolisms occur at a rate of approximately 1 % per patient-year, and bleeding complications occur at almost 0.5 % per patient-year. Thromboembolic and hemorrhagic events related to anticoagulant therapy should be considered during life-long follow-up. The occurrence rate of endocarditis reaches 0.5 % per patient-year, with a poor postoperative survival. Structural dysfunctions have been largely overcome, and the nonstructural dysfunction rate is 0.4–1.2 % per patient-year. The nonstructural dysfunctions induced by paravalvular leaks and pannus ingrowth are also issues that need to be resolved.

show abstract

The Sorin Bicarbon over 15 years clinical outcomes: multicentre experience in 1704 patients☆

Abstract: The SBP continues to perform satisfactorily even in the long term with low incidence of valve-related mortality and morbidity confirming to be an extremely reliable and durable mechanical valve substitute.

Cited by 19 publications

References 23 publications

Fifteen-year experience with the Bicarbon heart valve prosthesis in a single center

Fifteen-year experience with the Bicarbon heart valve prosthesis in a single center

Comparative studies of modern mechanical valve prosthesis (review)

Valve-related complications after mechanical heart valve implantation

Contact Info

Product

Resources

About